Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Pharmaceutical Benefits Under State Medical Assistance Programs, 2007

Pharmaceutical Benefits Under State Medical Assistance Programs, 2007

This report, part of the Pharmaceutical Benefits Under State Medical Assistance Programs series, is a compilation of data under state medical assistance programs (Title XIX) or state public medical assistance programs (prior Titles of the Social Security Act). It presents a general overview of the characteristics of state programs together with more detailed information on the pharmaceutical benefits provided. The data collection effort covers all states with Medicaid programs.

The information in this book is summarized in the following sections:

  • Section 1: Introduction.
  • Section 2: Overview of the Medicaid program, details about Medicaid managed care enrollment, including a breakdown by plan type and enrollment by plan type and a synopsis of 1915(b) waivers and 1115 demonstrations.
  • Section 3: Socio-demographic statistics and a description of the Medicaid certified facilities in each state.
  • Section 4: Medicaid pharmacy program characteristics, drawn largely from the NPC annual survey of state program administrators.
  • Section 5: Detailed profile of the states’ Medicaid pharmacy program (including medical assistance benefits and eligibles, drug payments and recipients, benefit design, pharmacy payment and patient cost sharing, use of managed care and state contacts.
  • Section 6: Profiles of State pharmaceutical assistance programs.

2007 marked the last year that this compilation was published.

Blog Post

The Role of Pharmaceuticals in Health Insurance Exchanges

As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...
Blog Post

Evidence, Coverage and Incentives: Challenges in Personalized Medicine

Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...
Blog Post

US v. Caronia: Related Resources

The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...
Blog Post

US v. Caronia and CER Communications

A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (...
Press Release

Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity

(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Press Release

NPC Conference to Address Questions on Ability to Share Health Research Findings Health

(Washington, DC, February 6, 2012)--To examine key issues around asymmetries, or inequalities, in communicating health information coming from the...
Press Release

National Pharmaceutical Council Selects Five Research Projects for Funding

Washington, DC (January 30, 2012) – The National Pharmaceutical Council (NPC) today announced that it has selected five projects related to...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
Commentary and Testimony Page

High Stakes for Setting Research Standards

What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
Commentary and Testimony Page

Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making

The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...
YouTube Videos

PCORI Outlines Efforts to Engage Patients

Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...
YouTube Videos

AEI's Gottlieb on Ability to Communicate CER Findings

American Enterprise Institute's Dr. Scott Gottlieb discusses legal and regulatory challenges facing various health care stakeholders in their...
YouTube Videos

UPenn's Dr. Caplan on Communicating CER to Patients

Univ. of Pennsylvania Director of the Center for Bioethics Dr. Art Caplan outlines an ethical framework for communicating comparative effectiveness...
YouTube Videos

Prioritizing CER: Assessing Public Health & Being Open With the Public

NPC Chief Science Officer Dr. Robert Dubois discusses an optimal decision-making process that could be utilized by research organizations in setting...
Blog Post

The Role of Pharmaceuticals in Health Insurance Exchanges

As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...
Blog Post

Evidence, Coverage and Incentives: Challenges in Personalized Medicine

Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...
Blog Post

US v. Caronia: Related Resources

The 2nd U.S. Circuit Court of Appeals' recent decision on United States vs. Caronia raises a big question for the pharmaceutical industry: will the...
Blog Post

US v. Caronia and CER Communications

A landmark appeals court ruling could open the door for the pharmaceutical industry to discuss information about comparative effectiveness research (...

Research

Pharmaceutical Benefits Under State Medical Assistance Programs, 2005

This report, part of the Pharmaceutical Benefits Und

Pharmaceutical Benefits Under State Medical Assistance Programs, 2004

This report, part of the Pharmaceutical Benefits Und

Pharmaceutical Benefits Under State Medical Assistance Programs, 2003

This report, part of the Pharmaceutical Benefits Und

  •  
  • 1 of 41
  • >

Commentary & Testimony